source
- Pfizer partners with China's Innovent Biologics on $10 billion cancer drug collaborationPfizer announced a major partnership with Chinese biotech Innovent Biologics, valued at over $10 billion, to develop cancer therapies. The agreement covers up to 12 antibody-based candidates, incl…
- Pfizer partners with China's Innovent Biologics on $10.5 billion deal for 12 early-stage cancer programsPfizer announced a collaboration with Innovent Biologics of China to develop a suite of cancer therapies. The agreement covers up to 12 early-stage antibody‑drug conjugates and multi‑specific anti…